INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 204 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2015. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,595,648 | +61.4% | 193,940 | -3.7% | 0.02% | +61.5% |
| Q2 2023 | $2,228,148 | -2.4% | 201,460 | +21.9% | 0.01% | -18.8% |
| Q2 2022 | $2,283,000 | -14.6% | 165,310 | +0.7% | 0.02% | 0.0% |
| Q1 2022 | $2,672,000 | +0.4% | 164,210 | +0.5% | 0.02% | +6.7% |
| Q4 2021 | $2,662,000 | +8487.1% | 163,385 | +81592.5% | 0.02% | +1400.0% |
| Q4 2014 | $31,000 | -86.9% | 200 | -80.0% | 0.00% | -90.0% |
| Q3 2014 | $237,000 | – | 1,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |